Compare HSTM & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HSTM | VALN |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 642.6M | 536.9M |
| IPO Year | 1999 | 2021 |
| Metric | HSTM | VALN |
|---|---|---|
| Price | $21.57 | $5.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $28.00 | $15.50 |
| AVG Volume (30 Days) | ★ 160.5K | 126.2K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $304,064,000.00 | N/A |
| Revenue This Year | $9.45 | N/A |
| Revenue Next Year | $5.12 | $93.87 |
| P/E Ratio | $35.18 | ★ N/A |
| Revenue Growth | ★ 4.26 | N/A |
| 52 Week Low | $19.50 | $5.15 |
| 52 Week High | $34.13 | $12.25 |
| Indicator | HSTM | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 57.37 | 28.77 |
| Support Level | $20.99 | N/A |
| Resistance Level | $21.72 | $6.42 |
| Average True Range (ATR) | 0.53 | 0.28 |
| MACD | 0.09 | 0.09 |
| Stochastic Oscillator | 84.77 | 26.77 |
HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.